Correlates of protection induced by vaccination.
Clin Vaccine Immunol. 2010; 17: 1055-1065
Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development.
J Virol. 2013; 87: 9939-9942
A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.
J Biol Chem. 2004; 279: 3197-3201
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.
Immunity. 2020; 52 (): 971-977
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Nat Struct Mol Biol. 2020;
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.
Science. 2020; 369: 956-963
Potent Neutralizing Antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B Cells.
Cell. 2020; 182 (): 73-84
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
Nature. 2020; 584: 120-124
Targets of T Cell Responses to SARS-CoV-2 coronavirus in humans with COVID-19 Disease and Unexposed Individuals.
Cell. 2020; 181 (): 1489-1501
Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.
Sci Immunol. 2020; 5
Long-lived T follicular helper cells retain plasticity and help sustain humoral immunity.
Sci Immunol. 2020; 5
Revealing the role of CD4(+) T cells in viral immunity.
J Exp Med. 2012; 209: 1391-1395
An mRNA Vaccine against SARS-CoV-2 – preliminary report.
N Engl J Med. 2020;
An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates.
Sci Transl Med. 2020; 12
DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
Science. 2020;
Immunogenicity of a DNA vaccine candidate for COVID-19.
Nat Commun. 2020; 11: 2601
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet. 2020;
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
N Engl J Med. 2020;
Development of an inactivated vaccine candidate for SARS-CoV-2.
Science. 2020; 369: 77-81
Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.
Immunol Res. 2007; 39: 225-239
Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.
PLoS One. 2012; 7: e35421
A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
Nature. 2020; 584: 353-363
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
N Engl J Med. 2020;
SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses.
2020 ()
Correlates of adjuvanticity: a review on adjuvants in licensed vaccines.
Semin Immunol. 2018;
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.
Sci Transl Med. 2011; 3 ()
Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response.
Vaccine. 2007; 25: 6618-6624
Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want.
NPJ Vaccines. 2018; 3: 51
Engineered immunogen binding to alum adjuvant enhances humoral immunity.
Nat Med. 2020; 26: 430-440
Adsorption onto aluminum hydroxide adjuvant protects antigens from degradation.
Vaccine. 2020; 38: 3600-3609
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Nature. 2020;
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
Science. 2020; 367: 1260-1263
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
Lancet Infect Dis. 2019; 19: 1091-1100
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.
Vaccine. 2014; 32: 7098-7107
Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6 ‘-dibehenate) – a novel adjuvant inducing both strong CMI and antibody responses.
Bba-Biomembranes. 2005; 1718: 22-31
Different human vaccine adjuvants promote distinct antigenin-dependent immunological signatures tailored to different pathogens.
Sci Rep-Uk. 2016; 6
Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein.
J Infect Dis. 2015; 212: 978-989
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.
J Immunol Methods. 2014; 409: 131-146
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
Nat Commun. 2020; 11: 4420
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.
Trends Immunol. 2020; 41: 355-359
Structures and distributions of SARS-CoV-2 spike proteins on intact virions.
Nature. 2020;
Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control.
Electrophoresis. 2020; 41: 1137-1151
Expanded Programme on I. Manual for the production and control of vaccines: pertussis vaccine. Geneva:.
1977 ()
Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.
J Pharm Sci. 2011; 100: 388-401
Control of antigen-binding to aluminum adjuvants and the immune response with a novel phosphonate linker.
Vaccine. 2013; 31: 4362-4367
Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response.
Vaccine. 2009; 27: 888-892
Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination.
Proc Natl Acad Sci U S A. 2016; 113 ()
Germinal center B cell and T follicular helper cell development initiates in the interfollicular zone.
Immunity. 2011; 34: 947-960
Vaccine adjuvants differentially affect kinetics of antibody and germinal center responses.
Front Immunol. 2020; 11579761
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.
Am J Epidemiol. 1969; 89: 422-434
Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
J Virol. 2015; 89: 2995-3007
Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.
Elife. 2020; : 9
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.
Science. 2020;
Expanding roles for CD4(+) T cells in immunity to viruses.
Nat Rev Immunol. 2012; 12: 136-148
A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.
J Virol. 2011; 85: 12201-12215
Overcoming CD4 Th1 Cell Fate Restrictions to Sustain Antiviral CD8 T cells and control persistent virus infection.
Cell Rep. 2016; 16: 3286-3296
Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.
Blood Adv. 2017; 1: 2329-2342
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.
Sci Transl Med. 2011; 3
Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination.
J Clin Invest. 2020; 130: 662-672
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.
Proc Natl Acad Sci U S A. 2017; 114 ()
Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients.
Clin Infect Dis. 2020;
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
Lancet Respir Med. 2020; 8: 420-422
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020; 395: 497-506
COVID-19 vaccine design: the Janus face of immune enhancement.
Nat Rev Immunol. 2020; 20: 347-348
Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease.
Nat Immunol. 2017; 18: 104-113
